Good day, and thank you for standing by. Welcome to the Dentsply Sirona Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Andrea Daley, Vice President of Investor Relations. Please go ahead. Thank you, Amy, and good morning, everyone. Welcome to the Dentsply Sirona Third Quarter 2023 Earnings Call. Joining me for today's call is Simon Campion, Chief Executive Officer, Glenn Coleman, Chief Financial Officer, and Andreas Frank, Chief Business Officer. I'd like to remind you that an earnings press release and slide presentation related to the call are available in the investor section of our website at www.dentsplysirona.com. Additionally, historical financial data related to our new segments is also available on our website. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today's call, we may make certain predictive statements that reflect our current views about future performance and financial results. We base these statements on certain assumptions and expectations on future events that are subject to risks and uncertainties. Our most recently filed Form 10-K and any updating information in subsequent SEC filings list some of the most important risk factors that could cause actual results to differ from our predictions. Additionally, on today's call, our remarks are based on non-GAAP financial results. We believe that non-GAAP financial measures provide investors with useful supplemental information about financial performance of our business, enable the comparison of financial results between periods, where certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business. Please refer to our press release for the reconciliation between GAAP and non-GAAP results. Comparisons are provided, are provided versus the prior year quarter, unless otherwise noted. A webcast replay of today's call will be available on the investor section of the company's website following the call. With that, I will now turn the call over to Simon. Thank you, Andrea, and thank you all for joining us this morning for our Q3 2023 earnings call. Today, I'll start by providing an overview of our recent performance, and then Glenn will cover Q3 results and the revised 2023 outlook. Before we discuss recent performance, I wanted to comment on the recent events in the Middle East. I am deeply saddened by the horrific terrorist attacks on Israel and the continued injuries and loss of innocent lives. We have over 300 employees in the country, and the safety of our employees and their families is our utmost priority. Currently, our business in Israel remains operational, and Glenn will touch upon this topic again when he covers the outlook assumptions. I would like to remind you all that we are hosting our Investor Day next Thursday, November 9, where we plan to cover our strategy and three-year plan in more detail, including the path to the adjusted EPS target of $3. As such, for today's call, our prepared remarks will be brief and focused primarily on a few key messages: Q3 financials and our outlook for the rest of the year. Now, starting on slide 4, in Q3, we continued to execute on our strategic plans to transform the business to deliver sustainable performance over the long term. We are making meaningful progress on our objectives, despite the challenging macroeconomic conditions that negatively impacted top-line growth in the quarter and led to the revised 2023 outlook. The business experienced headwinds in certain markets, particularly Germany and the U.S. I'm sure you've seen the data from ADA, and I'll comment momentarily on our own survey data. There were, however, some bright spots in the quarter, including 20% growth in China and double-digit growth in our U.S. CAD/CAM business. Our aligners business with Byte and SureSmile also delivered another quarter of double-digit growth. In Q3, our EBITDA margins expanded 70 basis points, with additional contributions generated by our restructuring program. These initiatives remain on track to deliver the full $200 million run rate savings by mid-2024. Additionally, today, we announced our plan to execute $150 million in share repurchases during the fourth quarter. Despite the headwinds we faced in the quarter, we continued to build capability and stay focused on our transformation journey. Now, moving to slide five, let's start with DSOs. We're seeing positive results from our reinvestment into our relationships with DSOs. We continue to repair, rebuild, and refocus on our relationships with this important and growing customer segment. While performance in this quarter was flat sequentially, we are building positive momentum with a healthy funnel of DSO opportunities over the next several quarters. We are also fulfilling our renewed commitment to clinical education. Our live education events, such as DS World, serve as an important component of our overall clinical education infrastructure. These events give us the opportunity to engage with customers and provide unparalleled clinical education. This year, we hosted four DS World events in the U.S., Spain, Italy, and Dubai, with three held this past quarter. Approximately 7,000 participants attended globally, and we delivered over 250 education courses. At DS World in Las Vegas, we presented the future of care. We believe DS Core will play an increasingly important role in delivering the future of care, as the digital paradigm shift connects products and technologies in delivering care to patients. It's a key element of our strategy, and we highlighted expanding features at this year's event. Now, of course, we continue to focus on innovation. We recently launched a new SureSmile Simulator on DS Core, which has generated positive feedback. Customers have highlighted patient experience and efficiency benefits with the integration of the simulator into DS Core. We have also released updates to DS Core, including the Communication Canvas and lab ordering and viewer functionalities. We are particularly pleased with the Communication Canvas, as it enables customers to highlight the entirety of a patient's clinical data and proposed treatment plan in one place. Anecdotal commentary from customers indicates that it drives an increase in treatment acceptance rates with customers. We look forward to discussing and showcasing DS Core's capabilities in greater depth at our Investor Day next week. I'd also like to highlight OSSIX Agile, which we recently launched as part of our implants bone regeneration portfolio. Implants clearly remained an important part of our business, and while we have a robust portfolio, we continue to increase the capabilities of our commercial teams, expand investment in clinical education, and incentivize commercial execution. Finally, in Q3, we continued our cadence of quarterly regional business review meetings, with meetings in APAC and LATAM. These meetings provide us the opportunity to dive deeper into each business and to engage with employees and customers. As a result of these reviews, we have identified key opportunities in each region for potential growth investments and have already taken action on some. The consistent and highly positive feedback from our employees and customers strongly supports continuing this in 2024. Now, just before I turn it over to Glenn to discuss our third quarter results in more detail, I'd like to take a moment to comment on our revised outlook. As we continue to focus on the transformation of our organization, including driving greater discipline and accountability, customer centricity will continue to stand as a core theme. As such, we believe our quarterly surveys have helped inform us and you of market trends. The weak sentiment in Australia and Germany in Q1, followed by reduced sentiment in Germany in Q2, led us to exhibit caution during our Q2 earnings call in August, especially given our presence in Germany. With continued negativity among German and Australian customers, in addition to reduced patient volume trends in the U.S., we decided to revise our outlook, which now sits within the guidance ranges set at the beginning of the year, despite a worsening macroeconomic environment. With that, I'll hand it over to Glenn. Glenn? Thanks, Simon. Good morning, and thank you all for joining us. Today, I'll provide more detail on our third quarter results and an update on our full year 2023 outlook. Before doing so, I'd like to comment on the $302 million non-cash after-tax charge in Q3, related to goodwill and other intangible asset impairments, primarily impacting our Connected Technology Solutions segment. We recorded this charge as a result of adverse macroeconomic factors, including weakened demand, particularly in Europe, as well as increased discount rates, reflecting the higher interest rate environment. Let me now move to our third quarter financial results. These trends impacted our top-line results, which came in below expectations. Despite this pressure, our transformation and organizational alignment work enabled us to expand EBITDA margin 70 basis points, and with a lower tax rate, resulted in adjusted EPS growth of 20% year-over-year, in line with our projections. Let's now move to slide six. Our third quarter revenue was $947 million, with reported and organic sales essentially flat year-over-year. Foreign currency was slightly favorable in the quarter, however, was lower than anticipated due to a stronger U.S. dollar. On a constant currency basis, we saw strong sales performance in China, which grew 20% year-over-year and improved sequentially from Q2. In addition, our global aligners business grew 10%, and CAD/CAM grew double digits in the U.S. These improvements were offset by softer demand in key markets such as Germany and the U.S., most notably impacting imaging, implants, and consumables. Despite flat revenue performance year-over-year and continued inflationary headwinds, adjusted EPS in the third quarter was $0.49, up 20%. The improvement was primarily driven by adjusted EBITDA margin expansion of 70 basis points to 18.2%. As a result of cost reductions from our restructuring program, effective cost management, and the benefit of price increases implemented earlier in the year. We achieved this while continuing to invest in our commercial teams and infrastructure. In addition, our adjusted EPS growth was impacted by a lower tax rate due to a favorable geographic mix....In the third quarter, we generated $134 million of operating cash flow, up 23% year-over-year, driven by improved profitability, a lower build of inventory, and the timing of accounts receivable and accounts payable compared to the prior year. Free cash flow conversion in the quarter was 93%, compared to 88% in the prior year. As a reminder, our long-term goal is to achieve 100% free cash flow conversion on a consistent basis once we move past the cash outlays associated with our transformation initiatives. Cash and cash equivalents amounted to $309 million at September 30, and our leverage ratio improved to 2.5x, which is in line with our long-term targeted rate. In the third quarter, we returned $29 million to shareholders through dividends, with a total of $236 million returned year to date, through a combination of dividends and share repurchases. As Simon noted, we also announced this morning that we intend to repurchase an additional $150 million of shares by year-end. Let's now turn to third quarter segment performance on slide seven. Starting with CTS, our Connected Technology Solutions segment, organic sales declined 4.6%. Within CTS, our global CAD/CAM business grew low single digits, driven by higher wholesale volume in the U.S. as distributors increased inventory ahead of DS World in September. Underlying U.S. CAD/CAM retail demand was also strong, particularly for Primemill and CEREC Primescan. The equipment and instruments business declined high single digits in the quarter due to softening demand for imaging equipment in the U.S. and Europe, which we attribute to rising interest rates and recessionary concerns in the market. In the near term, we are working with our distribution partners on financing alternatives to support our customers. Moving to EDS, or the Essential Dental Solutions segment, which includes endo, resto, and preventive products, organic sales declined about 1%, driven by lower volumes in the U.S. and Europe. We did see strength in the rest of the world, which mitigated some of this negative impact. Shifting to the orthodontic and implant solutions segment, organic sales grew 3.7%. Aligners grew double digits for the fifth consecutive quarter. This strong performance was driven by growth in both SureSmile and Byte. SureSmile grew 13% and continues to benefit from market share gains, new product offerings, and differentiated outcomes. Our direct-to-consumer aligner brand, Byte, grew 7% as we saw higher customer conversion rates. On a full year basis, we expect our aligners business to grow double digits, but anticipate single-digit growth in the fourth quarter, given macro pressures in our largest markets. Implants and prosthetics grew low single digits in the quarter, highlighted by increased demand for value implants, as well as growth in China due to VBP and market share gains. On a sequential basis, China implants grew 30% in the third quarter. Wrapping up with the Wellspect HealthCare segment, organic sales grew 6.8%, with growth across all three regions. Wellspect also benefited from new product launches with Navina Mini, a minimally invasive irrigation product for bowel care, and the LoFric Origo flexible, an intermittent male catheter, both of which have been well received by customers. For Q4, we expect a further acceleration of growth in Wellspect to about 10% year-over-year. Now, let's turn to slide 8 to discuss third quarter financial performance by region. U.S. sales declined about 1% due to lower sales of imaging equipment, implants, and restorative products, partially offset by strong growth in aligners and CAD/CAM equipment. U.S. CAD/CAM distributor inventory levels increased sequentially in the quarter by approximately $20 million, driven by a normal build in advance of DS World Las Vegas in September. We expect that most of this will support installs in Q4, and because of this, inventory levels will likely be lower by the end of the year. Turning to Europe, organic sales declined 2.8%, due primarily to lower EDS and CTS demand, as we continue to see prolonged recessionary impacts in Germany, our second largest market globally. Excluding Germany, organic sales in Europe were flat compared to the prior year. That said, we posted strong performance in the Wellspect segment and with our SureSmile aligners. Rest of World organic sales grew 4.5% in the quarter, led by China, which delivered significant growth in implants and EDS. With the strong third quarter performance, our year-to-date sales growth in China has now turned positive, with volume increases more than offsetting the pricing impact sooner than expected. Latin America, a smaller but fast-growing region for us, was another bright spot and grew double digits with improved performance in Brazil and Mexico. With that, let's move to slide nine to discuss our updated outlook for 2023. We expect to see current conditions continue to impact Q4. Our recent survey of over 1,000 dental customers together with other industry research data, suggests that we're seeing negative trends with decreased patient visits and increased cancellations. In addition, higher interest rates will likely result in deferral of some higher-end equipment purchases. These macroeconomic factors, coupled with a more unfavorable FX impact expected for the remainder of the year, have led us to lower our full year outlook. We now expect full year net sales to range from $3.90 billion-$3.94 billion. This includes an additional FX headwind of $25 million compared to our prior outlook. We expect organic sales to grow about 1% compared to our prior estimate of about 3% growth. Regarding Israel, I'd like to echo Simon's comments. Our thoughts are with all the families impacted, including our colleagues that call Israel home, and their safety is the top priority. Israel is an important country where we have operations, including two implant manufacturing sites, that generate roughly 3% of our total sales. Initiatives are underway to move inventory, identify alternative resources, and limit potential supply disruptions. We continue to monitor the events closely, and while we have not seen a significant impact on our business to date, the situation remains fluid. Our Q4 outlook assumes minimal impact from the conflict in Israel. Moving to profitability, we estimate full year EBIT margin to be greater than 17%, down from the prior outlook due to lower expected sales and the impact of lower volumes and unfavorable absorption in our CTS business. Our updated outlook includes a lower tax rate due to geographic mix, largely driven by a reduction in pre-tax income projections in Germany, as well as a lower share count due to the $150 million of additional share repurchases that are planned in the fourth quarter. With these updates, full year adjusted earnings per share is now expected to be in a range of $1.80-$1.85, representing a $0.14 decrease compared to the midpoint of our prior outlook range. Of this amount, $0.11 is due to lower organic sales, $0.04 is due to lower CTS gross margins, given lower volume projections, and $0.03 is from additional FX headwinds. This is partially offset by a lower tax rate, which is a $0.04 tailwind. With that, I'll now open the call for questions. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. All participants will be allowed one question and one follow-up. Please stand by while we compile the Q&A roster. Our first question comes from Elizabeth Anderson with Evercore ISI. Your line is open. Hi, guys. Thanks so much for the question. I appreciate the updated thoughts on the demand environment, and outlook. That's, that's very helpful. I was wondering if you could help us bridge, like, has anything changed in your sort of how you think about the operational steps that you need to take to get to that $3 in EPS for 2026 based on the sort of changing macro environment? Thank you. No, Elizabeth, thanks for the question. The short answer is no. I mean, a lot of the progress towards the $3 is in our control, is not dependent on the macro environment. And so I will lay out next week at Investor Day what those specific actions are in quantification. You know, obviously, a piece of it is the macro environment improving, but most of the $3 bridge is things in our control, and so we're continuing to move forward with all the transformation initiatives that we've previously talked about. That being the restructuring program, we're on track to deliver $200 million of annualized savings by mid-2024, the SKU optimization and rationalization work that we're doing, the ERP work. And so all that's continuing, we're on track and in our control. So nothing has changed relative to our plans. Got it. Thank you. You mentioned that you're getting some momentum in the DSO segment. Can you talk about sort of what's driving that? I know you have, obviously, an increased sales focus there. Are there certain products that are resonating? Do you feel like you're gaining share in certain areas? How do you sort of see the opportunity for kind of land and expand? Anything you can provide on that would be helpful. Thanks. Sure. Good morning, Elizabeth. So, as you know, we invested in a more robust commercial footprint with DSOs last year, and we've a team leading our relationship with them. We are approaching them all with our broad portfolio. I think one of the things that particularly resonates with them is our ability to make workflows more efficient and to increase treatment acceptance. And that's actually came out in our survey results, as well. So we're having a lot of traction with DS Core with some DSOs. They're very interested in that and the capability that that can begin to bring to them. But it's like a lot of other things here. We need to focus on them. They are a growing segment. We will speak more to that next week at Investor Day. And so far, so good, and the engagement that we've received in return has been very positive and a big change in the past 12 months. Great. Thanks so much. One moment for our next question. Our next question comes from Kevin Caliendo with UBS. Your line is open. ... Hi, guys. Thanks for taking my question. You didn't call out any impact from some of the issues at one of the big distributors. Just wondering if that contributed at all in the quarter? Yeah, Kevin, thanks for the question. Short answer is no, there was no impact to Q3. Just to frame up the situation, though, I mean, Henry Schein is our largest distributor. We've disclosed the size of the impact to our business in our 10-K. But just to give you the rough order of magnitude numbers, annually, we do about $500 million of sales, which is about 12% of our consolidated revenues. Over half of those are in the U.S., about 20% in Germany, so those two markets alone represent 75% of the revenues, and it's mostly consumable products, so preventive and restorative products. Henry Schein has been a great long-term partner with us. We've been in regular contact with them over the last several weeks. We're doing everything possible to support, you know, what they need as they work through their internal issue. I think most importantly, we're making sure customers are being supported during this transition period and continuing to get product. I would just tell you that it's difficult for us to quantify right now the potential impact to our fourth quarter results, since we don't know how long the situation's gonna last and whether or not the orders for our products are actually gonna shift to any other distributors in the interim. So, you know, all that being said, I would just say we factored in some level of conservatism in our guidance for the potential modest level of disruption we may see in the fourth quarter, but no impact in the third quarter. And Kevin, I would just, just add to that, you know, Glenn has been in close contact with Ron South, their CFO, and I've been in touch with, with, with Stan Bergman as well. So all levels of the organization, or both organizations are, are working together to make sure that, customers are impacted to the least extent possible. That's super helpful, guys. Can I— If I can ask a quick follow-up? Understanding now we've heard from two of the other publicly traded dental companies, where the fourth quarter step down is pretty meaningful, you have the same. What are you seeing? Like, what did you see in October? Is that, is that what's predicating this, this sort of step down? Do you have, like, visibility going forward on, on the macro deteriorating? I'm just trying to... I think we're all wondering sort of what's really happening in the marketplace. Did something happen at the end of September into October, that worsened and is sort of underwriting the guidance that we're seeing across the space? Yeah. So Kevin, I would say a couple things. Number one, you know, relative to September, obviously, we saw a falloff that we were not expecting. And obviously, you typically would see an uptick in September coming off the summer months, and we didn't necessarily see that to the same extent as the previous years. You know, when we look at October, I would just caveat it by saying we have not closed our books for the month of October, but when looking at our daily sales trends, you know, it's pretty consistent with what we've seen in September. And if I exclude China from our September results, where we had an easier comp, pretty much most of our businesses were down because of the macro environment. Clearly, there was a step down in September, and as we look at Q4, and how it started off, pretty consistent with what we see in September. So that's the reason why we've dropped our forecast here, in the fourth quarter. And obviously, we spent a lot of time with customers and do a survey, so maybe, Simon, you can comment on some of the feedback we got on our survey as well. Sure. So, Kevin, you know, as you know, you know, 65% or so of our businesses is outside the U.S., so we do this global survey, and we had over 1,000 respondents this quarter with more than 100 in every geography that we surveyed, U.S., Germany, France, Italy, China. And you know, the themes are common. Patient cancellations are up, volumes are down. In fact, 40% of those surveyed said that they did not have enough appointments coming into their clinics. You know, sentiments in Germany declined a small little bit. The U.S. was flat, and Australia and New Zealand was flat as well. So it's not all doom and gloom, but there are some indicators that around volumes and cancellations that are driving some of our thoughts here. You know, Brazil, for example, is positive. So a bit of a mixed bag. But again, as I answered to the previous question, the opportunities for us, we feel, in environments like this are, customers are looking for more efficient workflows. They're looking for an increase in treatment acceptance. I think that's why our Communication Canvas and DS Core can help, and they're looking to do more profitable procedures. So, we feel we're in a good position with the technologies that we offer to help customers grow their business and be more profitable, even in light of the macroeconomic conditions. Super helpful. Thank you. Thank you so much, guys. See you next week. Thanks. One moment for our next question. Our next question comes from Nathan Rich with Goldman Sachs. Your line is open. Hi, this is Sarah on for Nate. Thank you so much for taking our question. I guess just going back to the demand pullback and macro weakness, how are you thinking in just Q4 about the impact by segment and relative, and the relative performance you're projecting for Q4? Yeah, so I'll take that one. You know, we're not gonna give specific guidance by segment. I did give some color, though, in my prepared remarks. So, in orthodontics, we're projecting to have low single-digit growth or single-digit growth. Obviously, that's a slowdown from what we saw the past five quarters. It's a combination of the macro environment for SureSmile, and also Byte and some likely pressures we're gonna see with the student loan repayments being put back in place. And so we're being a bit more cautious on ortho, although we still expect to see growth in the fourth quarter. We expect to see very strong growth out of Wellspect, a lot of that driven from new products, so close to 7% organic growth in the third quarter. I mentioned, you know, double digit growth here in the fourth quarter. So those are our two segments that we expect to grow. You know, when we look at CTS, we are down about 4.5% or so in the third quarter. Modeling something probably pretty consistent with that as we go into Q4. So we're not expecting really any improvement in the overall segment there. And then for EDS, again, we're probably projecting to be flat, plus or minus a point there. So that just gives you some high-level color for the segments. Helpful. And then just going off Kevin's question on the Henry Schein distribution, have you seen any change so far in ordering patterns from the other distributors you work with? Yeah, not yet. I, I think it's still too early. You know, I think over the next couple of weeks, we'll play out and see how the other distributors' purchasing may change, but right now, haven't seen any significant impact or shift in our business. One moment for our next question. Our next question comes from Jeff Johnson with Baird. Your line is open. Jeff Johnson with Baird, your line is open. If you're on mute, please unmute yourself. Please stand by for our next question. Our next question comes from Justin Lin with William Blair. Your line is open. Hello, Justin Lin, if your line is. If you're on mute, please unmute yourself. Hi, Amy, can we go to the next question, please? All right, please stand by for our next question. Our next question comes from Jason Bednar with Piper Sandler. Your line is open. Hey, good morning. Can you hear me okay? Yes. We can. Thanks, Jason. Great. Thanks for taking the questions. I wanted to start on China. The growth there was pretty impressive, but there obviously is still the anti-corruption campaign that's been underway across that market. Are there any areas where you're feeling the effects from that campaign, do you think, that you know held back your growth at all in you know in any specific category or segment? Any challenges in interacting with doctors, training and education? And I guess along the same lines, have you seen that situation get any better? Has it improved here as we've gone August, September, October? Yeah, I don't think we've seen any change from the last several months, and we really haven't seen an impact on our business to date. We were very happy with the performance in China. I mentioned a strong year-over-year growth of 20%. Implants actually grew 30% sequentially, year-over-year, it almost doubled. So we had a really strong implants performance, and we're expecting to put up some very good growth here in the fourth quarter. I think one of the real positives, though, in China, is our implants business, actually, on a year-to-date basis, is now positive. So we fully offset all of the pricing erosion from VBP, and we're seeing really strong momentum on the volume side for implants. So on the whole, China is doing well. I would just say we see the same pressures, though, with our CTS business in China. So areas like imaging and some of the larger high-end equipment are down, and even with that, we're putting up 20% growth here in the third quarter. So it's not growth across the board. We are seeing some impact, like we're seeing in many other markets around the higher end equipment, as an example, but very happy with what we're seeing on implants and overall performance in China. I would just add to that. You know, we've, I think I spoke before, but we rolled out a new code of business conduct here at Dentsply Sirona. We're over 99.5% compliant to that internally now. And Asia Pacific, which obviously includes China, is 100% compliant to that. So, we said when we arrived here, we would take ethics compliance very seriously, and we've rolled that out, and the Chinese are also required to take that training on our behalf as well, so. All right. Very helpful. Thanks. For my other, other question, my follow-up here. There's plenty of evidence out there, adult orthodontics is pretty pressured right now. We've heard from your peers, same thing on this topic over the past week. Your orthodontic business is holding up, I'd say, relatively well. But I... You You know, Glenn, you talked about, you know, a little bit of a softer outlook in 4Q. We think about the investments you've been making in this category to stimulate growth. I'm just trying to put this all together and, you know, love to hear where you see the market and your business, again, the adult orthodontic part of the market, going over the next 12 to 18 months.... given, you know, these elements, the macro, the student loan repayment re, situation, restarting, SmileDirect filing, filing for bankruptcy, just, how, how do you see that part of the market right now? So let me jump in first, and then Glenn can get into some specifics, Jason. You know, in relation to SureSmile, we just launched the SureSmile Simulator, so we continue to innovate in those areas as well. That has gone very well. Our initial rollout is suggesting that treatment acceptance is up with respect to SureSmile because of this simulator. And we also are in pilot with the Byte+ program as well. So that has been well received by our pilot customers. So, you know, from an innovation and engagement perspective, we're doing well. Our NPS scores are up, particularly on the Byte program, and I'll hand it over to Glenn to deal with some of the specifics of your question. You know, I think when we look at the intermediate and longer term, this is a very attractive market, the fastest-growing area in dentistry. So, you know, we still see it as a strong, you know, mid-teens growth type market for us over the long term. The short-term situation, we're just being very cautious, given the macro environment, given what we're seeing with student loans and what that's gonna mean to our direct-to-consumer business. And I obviously, we look at the SmileDirectClub as an opportunity, so we'll see what happens there with respect to their bankruptcy announcement and what ultimately we could get from that. But right now we're being cautious going into the fourth quarter, which I think is prudent, just given the macro environment and some other things that we're seeing. But again, this is a top focus for us and an area that we think we can grow, you know, consistently in the double-digit range once we move past some of these acute pressures we're seeing in the short term. Okay, great. Thanks so much, guys. As a reminder, to ask a question, please press star one, one on your phone. One moment for our next question. Our next question comes from John Block with Stifel. Your line is open. Thanks, guys. Good morning. You know, is there a way to think about the headwinds that you experienced later in the quarter? You know, it just seems like the exit rate was heavily impacted or, you know, maybe call it the velocity of what was experienced in September. So where was that most acute? You know, I mean, looking just at your breakout, it seems like CTS, but was that US? Was it EMEA? Was it both? And then maybe more importantly, you know, Glenn, what's the assumption that you've embedded sort of for the balance of the year as we think about, you know, rounding out calendar 2023 in terms of what you factored into the guide? And then I'll just ask a quicker follow-up. Yeah, I think two things. One, we definitely saw a falloff in the U.S. and Europe. Those are the two major markets that we saw the drop, and it was really in CTS. Imaging, for sure, had probably the largest impact, even treatment centers, some of the instrument categories, but those were the areas that we saw the falloff. On the positive side, CAD/CAM and our milling, as well as our CEREC Primescan, had a really strong quarter overall, including the month of September relative to the U.S. business, so we were very encouraged by that. But, you know, most other categories, I would say, were down more acutely than we were expecting. And also, on the consumable side, we also did see a falloff. Now, part of that was some of the dealers reduced their inventory levels, so the retail demand doesn't necessarily reflect the wholesale sales that we show in our results. But, you know, even with that, I think consumables were a bit lighter as well, especially in restorative. Okay. In terms of the assumptions moving forward, John, I would just say we're assuming pretty much consistent trends from what we saw in September, and that's why we reduced our forecast here in the fourth quarter. Okay, that was very helpful. And you know, I'm guessing we're gonna obviously get more details next week on 2024, but let me just sort of noodle on something. You know, you got a lot of great disclosures in your releases, your presentations, and your Qs. I think this year, going into 2023, you know, you implemented some price increases. I think you at least alluded to that as, like, a driver, you know, of growth, if you would, in the first half of 2023, and now we've got a more difficult environment, right, with macro. And so when we think about 2024, is there pricing power in the portfolio, or was that lever really drawn down in 2023? When we start to frame 2024 top line, we think that might have to be a little bit more dependent on volume relative to price. Thanks, guys. Yeah, I would say, you know, we have benefited from price thus far in 2023, John. At this point, I would say we need to get after our volume more than get after our price, and that's what we're driving with our commercial teams globally. Some segments, for sure, as you well know, are being impacted by price, specifically scanners. And that's why we introduced Primescan Connect about a year ago, which has done pretty well for us globally. And we also, you know, reduced some price in certain geographies on our scanners, and we, that resonated with customers, and we saw volumes pick up. So we need to stop relying on price and get after volume for our sales growth, and because our plans need it as well. Thanks, Simon. One moment for our next question. Our next question comes from Jeff Johnson with Baird. Your line is open. Hey, guys. Let me try a different line here. Can you hear me now? ... Yep. All right, good. Thank you. Good morning. So Simon, I'm trying to respect the, you know, waiting till the Analyst Day next week for some of the comments around the LRP. But it sounds like you are reiterating your commitment to that $3 number in 2026. I just wanna make sure I'm hearing that correctly. And more importantly, I guess, Glenn, you know, as I think about that $3 number, you know, that you put out at the beginning of this year, obviously the US dollar has been much stronger this year. We've now got some end market concerns that have flared up for sure. We've got inflation that looks like it's staying more persistent and probably higher than would have been contemplated at least a year ago. So I guess my point is, or my question is, you know, have you tried to quantify how much incremental headwind, just from factors outside of your control, that have happened since you put that $3 number out? And, Simon, I would assume you're not gonna then cut back R&D or go-to-market commercialization spending or anything. So how do you kind of bridge that incremental headwind that has come up here across all those issues in the past year? Thanks. Good morning, Jeff. Firstly, you know, we will be reaffirming our $3 in 2026 at our Investor Day next week. And Glenn will walk through the bridge from where we are to the $3 during his session next week. For sure, we do not intend to reduce how we go to market or how we innovate. We simply need to be more judicious with where we innovate in and what we innovate in and how we spend our SG&A dollars so that we can get after, in my response to John's question a moment ago, we can get after volume with our sales force in all our geographies. So commercial and R&D are sacred to us. We just have to spend our money more wisely in those areas. Yeah, fair enough, Jeff, Jeff, sorry, I was just gonna comment on your other part of your question. So, you know, relative to the headwinds and impact to our $3, keep in mind, when we laid out the $3 target, our guidance for this year was $1.80-$2. So we're still within that guidance range, even though we've had a recent reduction. So we had just started off the year stronger, and obviously we're dealing with some headwinds at the moment. But when we laid that out, we're at $1.80-$2, and we're pretty much in that range. So that's why we're still confident that we can get to the $3. I will discuss more next week the path to get there, but probably the most important message and takeaway is most of the path to get to $3 is in our control and things that we've already completed or are in process. And so probably two thirds of the way there is all within our control and not dependent on the macro environment. And so I'll give more specifics next week, but I think that's a key point in why we're still confident we can get to the $3. Obviously, if the macro environment extends and is prolonged for, you know, a long period of time, it'll be much more challenging to get there. But our view is that this is more of a short-term, acute situation on the macro environment. All right. That's helpful. And then I guess as my follow-up question, just on the dental implant business, you know, I think, Simon, over the last month or two, we've heard you kind of maybe, you know, soften your view on when a turnaround, especially in that U.S. implant business, you might expect to see. I know you've been putting more sales reps out there. You've been putting more clinical education and other commercialization efforts behind that business, but talking about maybe that getting back to market a couple of years from now instead of more in the near term. You know, does that just take more spending there? Is it a pricing issue? Do you need to increase, you know, maybe your reliance on a lower priced product like MIS, notwithstanding, I guess, the Israel issues right now, but, you know, just how do you look at that implant business, the strategy there over the next year or two in trying to get that back to market? Thanks. Thanks, Jeff. So, you know, implants is a, it's a, it's a very interesting, a very interesting business. Nice growth, good margins, and we have not performed historically, in this space. We spoke before, I think on our Q2 call, about the, the portfolio survey work, that we were doing, and we completed that, in Q3 with over 2,000 respondents. And I would say overwhelmingly, and I don't use that word lightly, but, an overwhelming favorability with respect to our offering across all, categories, including implants. I think the band is a lot tighter in implants than it is in other areas. But, our customers, over 2,000 of them, have said that we have a robust portfolio in implants. But where we have work to do is around the capabilities of our commercial teams and the investments that we made in clinical education over the past number of years. So let me deal with the second, the second piece first. We have invested heavily in rebuilding relationships through our clinical education programs this year. We had a World Implants Symposium in Turkey earlier this year, with over 450... Sorry, Athens, Greece, earlier this year, with over 450 people attending. We just had another group of Polish clinicians in Warsaw attend an implants session. We continue to reinvest in rebuilding our relationship with implantologists through education. And then on the sales force capability, clinical capability side of things, you know, the turnover that we've experienced in our implant sales force over the past number of years has whittled the capability of that group down. And I think it's around 50% have about 12 months of tenure, including the new people that we brought on. We are training them heavily. We had a second or third training with that team in May. And you know, I think it's beginning to resonate. The challenge has been is that the accounts that we've lost, their volume is pretty significant. And as we bring on new accounts, it's not enough right now to offset those volume losses. However, we just had a complete business review, where we went through every sales manager in the U.S., and there are a lot of green shoots in terms of engagement with not only the implantologists, but also their referral network as well. So, for sure, it's taking longer than we would have hoped, but we're investing in the capability of our team. We're investing in rebuilding relationships with our customers and their network. And we're investing in customer education, which are the main things that came out from our survey. Thank you. I'm showing no further questions at this time. I would now like to turn the conference back to Simon Campion for closing comments. Thank you, everyone, for your attendance on, on today's call. I would like to reiterate some key points before, before we close. Firstly, we remain intently focused on driving value for all stakeholders through innovation and execution. Secondly, while the macro environment is uncertain, we see bright spots in the business and maintain our confidence in improving execution, which we believe will position us better to navigate external challenges. And thirdly, we look forward to hosting our first Investor Day next week, and I encourage you all to join us as we share details about our strategy and long-term plans. We will continue to prudently act in the best interests of the company and our stakeholders, including our investors, patients, customers, and employees. And finally, on behalf of the management team, I want to thank all Dentsply Sirona employees for their dedication to the business and the necessary transformation work that is underway. And we especially want to express our thanks to employees who have departed the organization in the last quarter and wish them all well in the next phase of their careers. This concludes today's conference call. Thank you for participating. You may now disconnect.